Cefixime Plus Doxycycline Compared to Ceftriaxone Plus Azithromycin for Treatment of Gonorrhoea

• Status: Completed
• Trial end date: 2022-12-22
• Target enrollment: 0
• Participant gender: All

Summary

A non-inferiority, open-label, multicentre randomised controlled trial to compare two therapeutic regimens for the treatment of uncomplicated urogenital, rectal or pharyngeal gonorrhoea in men and women between 18 and 75 years of age. Patients were enrolled and treated from April 2021 to June 2022 at the Dermatovenerology Department, University Hospital Bulovka, Prague, Czech Republic and the Venereology Prague, Medicentrum Beroun, Prague, Czech Republic.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bulovka Hospital
• Collaborator: Örebro University, Sweden
• Treatments: Azithromycin; Cefixime; Ceftriaxone; Doxycycline

Criteria

Inclusion Criteria:

• uncomplicated urogenital, rectal or pharyngeal gonorrhoea diagnosed using the nucleic acid amplification test

Exclusion Criteria:

• any antimicrobial treatment during the 4 weeks before study enrolment

• pregnancy or lactation

• autoimmune disease

• renal, hepatic or cardiac insufficiency

• immunosuppressive therapy

• allergy to cephalosporins, macrolides or doxycycline